Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
Copyright policy )Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
PCSK9 is a protease that degrades hepatic LDL-C receptors. Evolocumab and alirocumab are fully human monoclonal antibodies administered as subcutaneous injections that inhibit PCSK9, preserving receptor availability to clear circulating LDL-C.[1][1],[2][2] In randomized, placebo-controlled trials
Anticholesteremic Agents, Hypercholesterolemia, PCSK9 Inhibitors, Cholesterol, LDL, Antibodies, Monoclonal, Humanized, Atherosclerosis, Ezetimibe, Cardiovascular Diseases, Humans, Drug Therapy, Combination, Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents, Hypercholesterolemia, PCSK9 Inhibitors, Cholesterol, LDL, Antibodies, Monoclonal, Humanized, Atherosclerosis, Ezetimibe, Cardiovascular Diseases, Humans, Drug Therapy, Combination, Hydroxymethylglutaryl-CoA Reductase Inhibitors
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).2 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!